NeonMind Biosciences Inc (LCR) AI Stock Analysis

• Market Cap: $835.56K
• Dividend Yield: N/A
• Average Volume (3M): 99.13K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.58
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: CA
• Employees: 28
• Sector: Basic Materials
• Sector Strength: 61
• Industry: Industrial Materials
• EPS (TTM): -0.02
• Shares Outstanding: 55,703,873
• 10 Day Avg. Volume: 236,185
• 30 Day Avg. Volume: 99,132
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): 1564.70
• P/FCF Ratio: 9.50
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

NeonMind Biosciences Inc exhibits a challenging financial situation with no revenue, high leverage, and negative cash flows, significantly impacting its overall score. Technical analysis provides some stability signals, but the lack of valuation metrics suggests caution. The overall risk profile suggests a need for strategic changes or additional funding to improve its financial health.

NeonMind Biosciences Inc Business Overview & Revenue Model

Company Description

NeonMind Biosciences Inc (LCR) is a biotechnology company focused on developing innovative psychedelic-based treatments for mental health disorders. The company operates within the life sciences sector, leveraging the therapeutic potential of psychedelic compounds. Its core offerings include drug development programs aimed at addressing various mental health conditions, particularly depression and anxiety.

How the Company Makes Money

NeonMind Biosciences Inc generates revenue primarily through the development and commercialization of psychedelic-based therapies. The company seeks to advance its drug candidates through clinical trials and secure regulatory approvals, which can lead to partnerships or licensing agreements with larger pharmaceutical companies. These partnerships may provide upfront payments, milestone payments, and royalties on future sales. Additionally, NeonMind may explore opportunities in other sectors such as wellness products or services that align with its core focus on mental health, although specific details on these revenue streams are currently unavailable.

NeonMind Biosciences Inc Financial Statement Overview

Summary

NeonMind Biosciences Inc is facing significant financial challenges, with no current revenue generation, high leverage, and negative cash flows. This suggests a high-risk financial situation with potential liquidity issues and a need for strategic turnaround or additional funding to sustain operations.

Income Statement

NeonMind Biosciences Inc has reported no revenue in the most recent periods, indicating a lack of sales activity or operational revenue. The absence of gross profit, EBIT, and EBITDA suggests ongoing operational losses, while net income figures are unavailable for the latest period, implying a continuation of negative profitability trends seen in past reports.

Balance Sheet

The balance sheet reflects a challenging financial position with negative stockholders' equity, indicating liabilities exceed assets. The company has a high debt load relative to its equity, and negative equity raises solvency concerns, highlighting significant financial risk.

Cash Flow

The cash flow statement shows persistent negative free cash flow and operating cash flow, indicating cash outflows exceed inflows, which could impact liquidity. Financing activities are positive, suggesting reliance on external funding to maintain operations.

Breakdown
Mar 2024	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	415.80K
	Gross Profit
0.00	0.00	0.00	415.55K
	EBIT
―	-1.75M	-7.83M	-1.06M
	EBITDA
―	-1.75M	-7.83M	-1.06M
	Net Income Common Stockholders
―	-2.03M	-7.21M	-2.68M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
135.40K	69.91K	967.27K	1.17K
	Total Assets
719.33K	129.43K	1.34M	209.90K
	Total Debt
1.04M	846.94K	450.01K	691.25K
	Net Debt
984.93K	811.12K	-323.52K	690.08K
	Total Liabilities
1.33M	1.53M	1.05M	987.31K
	Stockholders Equity
-612.89K	-1.40M	290.30K	-777.41K
Cash Flow		Free Cash Flow
-1.31M	-1.22M	-5.82M	-853.45K
	Operating Cash Flow
-1.13M	-1.08M	-5.82M	-853.45K
	Investing Cash Flow
-36.15K	72.14K	389.12K	0.00
	Financing Cash Flow
627.93K	271.00K	6.20M	746.93K

NeonMind Biosciences Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:LCR, the sentiment is Positive. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and above the 200-day MA of 0.02, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 55.88 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:LCR.

NeonMind Biosciences Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TRIP	49 Neutral	$14.03M	―	-30.44%	―	13.57%	-14.29%
Sector *	49 Neutral	$1.95B	-1.61	-21.88%	3.78%	0.55%	-26.94%
RVV	46 Neutral	C$10.46M	―	-66.49%	―	―	-4.84%
CYBN	37 Underperform	$1.97M	―	-58.79%	―	―	51.37%
LCR	29 Underperform	$835.56K	―	0.00%	―	―	―